Trial · NCT04191616
Results by group11
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 11 of 11
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate (ORR) As Assessed by the Independent Review Committee (IRC) | Carfilzomib With Pomalidomide and Dexamethasone (KPd) | 57.7 | 90% Confidence Interval 45.4 to 69.3 | percentage of participants | |
| Percentage of Participants With a Minimal Residual Disease Negative Complete Response (MRD[-]CR) as Assessed by the IRC | Carfilzomib With Pomalidomide and Dexamethasone (KPd) | 3.8 | 90% Confidence Interval 0.7 to 11.6 | percentage of participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Carfilzomib With Pomalidomide and Dexamethasone (KPd) | 50 | Participants | ||
| Number of Participants Achieving MRD[-] Response | Carfilzomib With Pomalidomide and Dexamethasone (KPd) | 5 | Participants | ||
| Number of Participants With Sustained MRD[-]CR for at Least 12 Months as Assessed by the IRC | Carfilzomib With Pomalidomide and Dexamethasone (KPd) | 0 | Participants | ||
| Number of Participants With Sustained MRD[-]CR at Month 24 as Assessed by the IRC | Carfilzomib With Pomalidomide and Dexamethasone (KPd) | 0 | Participants | ||
| Kaplan-Meier Estimate of Duration of Response as Assessed by the IRC | Carfilzomib With Pomalidomide and Dexamethasone (KPd) | 20.3 | 90% Confidence Interval 9.2 to NA | months | |
| Time to Response as Assessed by the IRC | Carfilzomib With Pomalidomide and Dexamethasone (KPd) | 1.0 | Full Range 1 to 2 | months | |
| Kaplan-Meier Estimate of Progression Free Survival (PFS) as Assessed by the IRC | Carfilzomib With Pomalidomide and Dexamethasone (KPd) | 11.1 | 90% Confidence Interval 6.5 to NA | months | |
| Kaplan-Meier Estimate of Overall Survival (OS) | Carfilzomib With Pomalidomide and Dexamethasone (KPd) | 17.6 | 90% Confidence Interval 11.2 to 23.5 | months | |
| Number of Participants With Best Overall Confirmed Response of CR or Better as Assessed by the IRC | Carfilzomib With Pomalidomide and Dexamethasone (KPd) | 3 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04191616/results